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Abstract
Background: This trial aims at testing the efficacy of weekly reminder and motivational text messages, compared
to usual care in improving adherence to Highly Active Antiretroviral Treatment in patients attending a clinic in
Yaoundé, Cameroon.
Methods and Design: This is a single-centered randomized controlled single-blinded trial. A central computer
generated randomization list will be generated using random block sizes. Allocation will be determined by
sequentially numbered sealed opaque envelopes. 198 participants will either receive the mobile phone text
message or usual care. Our hypothesis is that weekly motivational text messages can improve adherence to Highly
Active Antiretroviral Treatment and other clinical outcomes in the control group by acting as a reminder, a cue to
action and opening communication channels. Data will be collected at baseline, three months and six months.
A blinded program secretary will send out text messages and record delivery.
Our primary outcomes are adherence measured by the visual analogue scale, self report, and pharmacy refill data.
Our secondary outcomes are clinical: weight, body mass index, opportunistic infections, all cause mortality and
retention; biological: Cluster Designation 4 count and viral load; and quality of life. Analysis will be by intention-
to-treat. Covariates and subgroups will be taken into account.
Discussion: This trial investigates the potential of SMS motivational reminders to improve adherence to Highly
Active Antiretroviral Treatment in Cameroon. The intervention targets non-adherence due to forgetfulness and
other forms of non-adherence.
Trial Registration: Pan-African Clinical Trials Registry PACTR201011000261458
http://clinicaltrials.gov/NCT01247181
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Background
Mobile text messages using the short message service
(SMS) are a cheap and non-invasive means of communi-
cation that can be used to convey health related messages
to owners of mobile phones. There is contradictory evi-
dence concerning the role of mobile phones in ameliorat-
ing health outcomes, especially in less developed
countries where private ownership and use of mobile
phones is not as widespread as in other more developed
countries [1]. Currently, Africa has the greatest uptake of
mobile phone technology [2].
The advent of Highly Active Antiretroviral Therapy
(HAART) has markedly reduced morbidity and mortality
associated with the Human Immune deficiency Virus
(HIV) [3]. Much effort has been put into the scaling up
of access to HAART [4]. The efficacy of HAART depends
largely on compliance to treatment regimens. Poor
adherence is associated with poor virological and immu-
nological response. It is also responsible for the develop-
ment of resistant strains [5]. Very high levels (> 95%) of
adherence are necessary for sustained clinical success [6].
Our search for papers on the use of SMS technology
to improve adherence to HAART revealed two protocols
for trials in Kenya (WelTel Kenya 1) [7] and India
(HIVIND) [8]. The WelTel Kenya 1 trial reported signif-
icant improvements in adherence and viral load [9].
The World Health Organization (WHO) has prioritized
the use of new technologies to assist health delivery in
resource-limited settings [10]. The SMS is already used for
business transactions, personal communication, advertis-
ing and betting. There is a potential for new benefits to be
discovered in the use of mobile phone technology in
health interventions for resource- limited countries [11].
In South Africa, the SMS has been demonstrated to
improve HIV health care service delivery by ameliorating
communication between health workers and patients, and
also as an appointment reminder [12].
Additionally, a Cochrane systematic review found that
mobile phone calls and reminders can improve adher-
ence to tuberculosis care [13]. Another study investigat-
ing the use of mobile phone technology to improve
adherence to HAART discouraged the use of phone
calls as they are time and labor intensive [14]. A third
study, investigating the use of text messaging to improve
adherence to primary care found that it was more cost
effective than phone calls[15]. The cost of phone calls
may also be a hindrance in developing countries. The
Indian trial [8] is testing automated phone calls coupled
to picture messages. This may reduce the time and
labor costs involved. Another study reported high satis-
faction with two way text messaging [16]. These findings
suggest that the more feasible application of the mobile
phone in health would be the SMS.
The goal of this trial is to assess whether sending
weekly motivational text messages via a mobile phone
versus no text messaging will improve adherence to
HAART and clinical outcomes among HIV positive
patients over a 6 month period. We hypothesize that
sending one weekly motivational reminder will produce
a change in behavior to enhance drug or treatment
adherence and hence clinical outcomes. SMS-delivered
interventions are capable of producing a positive beha-
vior change [17].
Participants will be selected from the Accredited
Treatment Centre (ACT) of the Yaoundé Central Hospi-
tal (YCH).
Methods and Design
The trial is registered with the Pan-African Clinical Trials
Registry http://pactr.org as PACTR201011000261458 and
with clinical trials.gov as NCT01247181.
Funding
Partial funding for this study was obtained from an
international postdoctoral research fellowship awarded
by the Canadian Institutes of Health Research (CIHR)
HIV Clinical Trials Network (CTN) to the principal
investigator.
Study Design
Using a 1:1 allocation ratio, patients at the Yaoundé
Central Hospital (YCH) Accredited Treatment Centre
(ATC) will be randomized to either receive a text mes-
sage reminder to take their medication or not (Figure 1:
Consolidated Standards of Reporting Trials-CONSORT
diagram of study design). Both groups of patients will
benefit from the usual care provided in this centre
which includes adherence counseling and rarely, home
visits.
Randomization
This is a parallel group design evaluating the effects of
adding weekly SMS text messages using mobile phones
to usual care (intervention) versus usual care alone
(control) among HIV positive patients on HAART. Eligi-
ble and consenting patients will be randomized to inter-
vention and control arms using 1:1 allocation ratio by
opaque sealed envelope method. A computer generated
randomization list will be generated using random block
sizes of 2, 4 and 6, by the Father Sean O’Sullivan
Research Centre Biostatistics Unit at St Joseph’s Health-
care/McMaster University. The allocation codes will
then be put in sequentially numbered opaque sealed
envelopes and administered by the trained Research
Staff at YCH ATC centre. Trained interviewers - blinded
to group allocation - will collect data using a pretested
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data collection form containing socio-demographic data,
clinical information and adherence rates at baseline, 3
and 6 months. The data analyst will also be blinded to
group allocation.
Trial Setting
Cameroon is a sub-Saharan central African country, made
of ten provinces and a population of 18 million inhabitants
[18]. The Centre and capital province has a population of
about 3.2 million inhabitants. The adult prevalence rate of
HIV in the country is 5.1% [19]. Subjects will be recruited
from the YCH ACT. This is an urban centre in the heart
of the capital city, Yaoundé. The adult prevalence of HIV
in the Centre province is 4.7%. The YCH is a tertiary level
general teaching hospital with a capacity of 381 beds. It
employs nearly 800 staff including 95 doctors and 270
nurses [20]. The ACT has a very high recruitment rate of
approximately 40 new cases per week and caters for 6500
regular clients. It is the largest HIV clinic in the country
and offers enormous potential for recruitment.
Participants: inclusion/exclusion criteria
We will include subjects who are aged above 21 years,
own a mobile phone and can read text messages, and
Assessedforeligibility
x >21
x Ownsamobilephoneandcanread
textmessages
x OnHAARTш1month
Enrolment
Randomization
Interventiongroup
x Usualadherencecounselling
x Weeklymotivationaltextmessages
Controlgroup
x Usualadherencecounselling
x Notextmessages
Baselinedatacollection
x SocioͲdemographic
x Clinical:WHO&CDCclassification,
OI,Wt,BMI
x Biological:CD4,Viralload
x Adherence
x Qualityoflife
FollowͲup(3monthsand6months)
x Clinical:OI,Wt,BMI
x Biological:CD4,Viralload
x Adherence
x Qualityoflife
x Allcausemortality
x Retention
FollowͲup(3monthsand6months)
x Clinical:OI,Wt,BMI
x Biological:CD4,Viralload
x Adherence
x Qualityoflife
x Allcausemortality
x Retention
Baselinedatacollection
x SocioͲdemographic
x Clinical:WHO&CDCclassification,
OI,Wt,BMI
x Biological:CD4,Viralload
x Adherence
x Qualityoflife
Targetenrolment=198
(Takingintoaccounta20%
attrition)
Exclusion
x OnHAARTfor<1month
x Doesn’tfulfilleligibilitycriteria
x Refusestotakepart
Figure 1 Consolidated Standards of Reporting Trials-CONSORT diagram of study design.
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who have been on HAART for at least a month.
Informed consent is a prerequisite for participating in
the study, and will be provided orally and in writing.
We will exclude participants who have been on
HAART for less than a month, are aged less than
21 years. Participants who have used HAART for at
least one month are chosen so that we can calculate a
baseline figure for adherence.
Intervention
We will send a short text message to the participants in
the intervention group in both French and English. The
content of the message will be motivating and will act
both as a reminder and a cue to action (Figure 2: Exam-
ple of a text message). The message will also contain a
phone number they can call back if they need help. The
content will be varied so as to retain participants’ atten-
tion throughout the period of the study and to explore
the various aspects of behavior change. The program
secretary will have a list of phone numbers to which he/
she will send the messages every week and will use the
‘delivery report’ function to ensure that the messages
have been delivered. One message will be sent per week
in the morning of a chosen day. The average cost for
text messages on any networks is 50 CFA Frs. CFA
(≈0.1 USD). Text messaging will be provided as an add-
on to usual care which includes regular HAART coun-
seling and occasional home visits.
Control
In the control arm, patients will receive the usual care
provided to all patients of the ATC which includes regu-
lar HAART counseling and occasional home visits. They
will be given a number to call if they have questions.
They will not receive any text messages, but they will be
interviewed at baseline, 3 months and 6 months.
Study Objectives
Primary Objective
The primary objective of this trial is to investigate the
effect of adding the SMS to usual care versus usual care
alone in improving and maintaining adherence to
HAART in HIV positive patients on HAART at 3 and
6 months. There are several methods used to evaluate
or measure adherence to medications, each with advan-
tages and disadvantages [21,22]. Thus, there is no gold
standard in measuring medication adherence [21,23].
The common approach is to use multiple methods to
compare or assess the robustness of the estimates of
adherence. For this study, we will use three commonly
used measures of adherence - namely Visual Analogue
Scale (VAS), Pharmacy Refill Data (PRD), and Self
Report (SR). We will use VAS as the primary method of
measuring adherence. The VAS is highly correlated with
more objective methods like using Microelectronic
Monitoring System (MEMS) caps [24]. VAS method has
also been widely used in several RCTs evaluating differ-
ent interventions including mobile text messaging to
enhance adherence to HAART [8,21]. PRD and SR will
be used to fill any missing data on VAS.
Secondary objectives
The secondary objectives include comparing clinical out-
comes such as weight, body mass index (BMI), opportu-
nistic infections (OI), Cluster Designation (CD) 4 count,
viral load and quality of life between the groups. These
comparisons will be performed at 3 and 6 months.
Outcome measures
Our primary outcome will be adherence rates, measured
using VAS. SR and PRD will also be used to supplement
VAS (Table 1).
Our Secondary endpoints will be;
• Clinical: Weight, BMI, opportunistic infections
• Biological: CD4 count, viral load
• Quality of life (QOL): Measured with the SF-12
QOL assessment form [25].
• All cause mortality
• Retention
Figure 2 Example of a text message.
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Duration
The trial will run for six months, with outcome assess-
ment at baseline, 3 months and 6 months.
Sample size
The sample size calculation is based on the test of the
null hypothesis that the rates of adherence to HAART
in the two groups (intervention and control) are equal.
The primary measure of effect is the rate of adherence
to ART treatment as measured by using the VAS over 6
months. The criterion for significance (alpha) has been
set at 0.05. The test is 2-tailed, which means that an
effect in either direction will be interpreted. The sample
size was calculated using the WINPEPI (PEPI- for-win-
dows) version 9.5 software [26]. With the proposed sam-
ple size of 82 in each of the two groups (i.e. assuming a
1:1 allocation ratio), the study will have power of 80% to
yield a statistically significant result using a chi-squared
test (assuming an intention-to-treat principle for the
analysis) of the relative risk at alpha = 0.05. This com-
putation assumes an adherence rate of 80% (for the
intervention group) versus 60% (for the control group)
at 6 months. These estimates are reflective of estimates
from similar studies investigating SMS effect on drug
adherences [27] and were modified to account for the
type of intervention and patients for this study. We
adjusted the sample size for a potential attrition rate of
20% (due to drop-outs) based on attrition rates to care
in this centre. Therefore, the required sample size is 198
patients (99 per group). At the YCH ATC, on average,
there are about 120 patients put on HAART per month.
We estimate that about 90% will have mobile phones
and would be eligible to participate in the study. Of
these, it is expected that approximately 75% would be
willing to participate in the study and will provide con-
sent to participate in the trial. The expected period for
recruitment will be one month to obtain 198 patients
needed for the trial. It is feasible to recruit 198 patients
in one month because we will also recruit from the
large pool of old patients. Our study is designed to
detect a 20% increase in adherence.
Analysis plan
The analysis and reporting of the results with follow the
CONSORT guidelines [28]. The statistician/data analyst
will be blinded to the study group. The process of patient
selection and flow throughout the study will be summar-
ized using a flow-diagram. The analysis results of patient
demographics and baseline outcome variables (both pri-
mary and secondary) will be summarized using descrip-
tive summary measures: expressed as mean (standard
deviation) or median (minimum-maximum) for continu-
ous variables and number (percent) for categorical vari-
ables. We will adopt an intention-to-treat principle to
analyze all outcomes, meaning that data from partici-
pants will be analyzed according to the group to which
they were randomized even if they do not receive the
allocated intervention. We will also use multiple-imputa-
tion [29] to handle missing data. We will use the T-test
for comparing groups on continuous outcomes and the
chi-squared test for binary outcomes. All statistical tests
will be performed using two-sided tests at the 0.05 level
of significance. The Bonferroni method will be used to
adjust the level of significance for testing for secondary
Table 1 Overview of outcome measures
Outcome measures Scale Type Measure Analysis method
Primary
Adherence at 6 months*
VAS Ordinal Binary VAS percentage >95% Chi-squared test
Self report Ordinal Binary % adherence in last month >95% Chi-squared test
PRD Ordinal Binary % of complete refills >95% Chi-squared test
Secondary
Weight Ratio Continuous Change in weight T-test
BMI Ratio Continuous Change in BMI T-test
OI Nominal Binary Occurrence of new OI Chi-squared test
Mortality Nominal Binary All deaths Chi-squared test
Retention Nominal Binary Number retained in care Chi-squared test
CD4 count Ratio Continuous Change in CD4 count T-test
Viral load Ratio Continuous Change in viral load T-test
Satisfaction with care Ordinal Categorical Change in satisfaction scores T-test
QoL Ordinal Categorical Change in QoL scores T-test
VAS: visual analogue scale, PRD: pharmacy refill data, BMI, body mass index, OI: opportunistic infection, CD4: Cluster Designation 4, QoL: Quality of Life.
*All three measures of adherence will also be analyzed as continuous outcomes using T-test.
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outcomes to keep the overall level at alpha = 0.05. For all
group comparisons, the results will be expressed as effect
(or risk ratio for binary outcomes), corresponding two-
sided 95% confidence intervals and associated p-values.
P-values will be reported to three decimal places with
values less than 0.001 reported as <0.001. Adjusted ana-
lyses using the following baseline covariates (age, gender,
education, duration on HAART, HIV staging, nutritional
status (BMI) and the presence or not of an opportunistic
infection (OI)) will be performed using regression techni-
ques to investigate the residual impact of key baseline
characteristics on the outcomes. Goodness-of-fit will be
assessed by examining the residuals for model assump-
tions and chi-squared test of goodness-of-fit. All analyses
will be performed using SPSS (Statistical Package for the
Social Sciences) version 16.0 for Windows.
Adherence will be measured both as a continuous out-
come (change in adherence) and as a binary outcome i.e.
adherent (95% of pills taken) or non adherent (< 95% of
pills taken). In literature, adherence data can be handled
in a number of ways. The measures can be reported as
the number of doses respected or can be combined into a
composite score [21]. Even though combined measures
are more correlated to clinical response, they are not very
practical [22]. The data from the various adherence mea-
sures will not be merged. We will report the effects of
the intervention on all the measures of adherence used,
and compare them for discrepancies.
Additional studies
• Adherence rates: We will use this opportunity to
calculate the rates of adherence to HAART in the
YCH ATC. The context of adherence to HAART in
Cameroon has changed greatly over time and the rates
reported in literature were subject to cost (which has
been dropping over time), availability, accessibility,
study design, technique used to measure adherence
and study setting. These rates vary from 10% to 97%
[30-32]. This study will provide a more accurate and
current estimate of adherence in Cameroon.
• Safety: Data will be collected on issues that may
arise from the use of text messages to improve
adherence.
• Health worker experiences: Self-administered
questionnaires will be used to assess health worker
perceptions of the intervention in terms of long
term use, additional workload and benefits to care.
The applicability of such an intervention will depend
largely on its acceptability by health workers.
Ethical Considerations
The trial will be conducted in compliance with the local
protocol and applicable regulatory requirements in
Cameroon. The study has been approved by Cameroon
National Ethics Committee. Any deviations from the
protocol will be reported and explained. The study will
be conducted in accordance with the Helsinki declara-
tion [33] and other established clinical practice guide-
lines for research on human subjects. Research
personnel will approach all potentially eligible patients
who fulfill eligibility criteria for consent. All patients
must sign a consent form to participate in the trial.
Discussion
The potential of mobile phone technology to improve
health outcomes is a domain worth exploring, especially
in this era of increased uptake and dependence on
mobile phones. Studies investigating the use of text
messages to improve adherence have yielded varied
results [12,16,34].
Improving adherence to HAART can play a key role
in reducing morbidity and mortality due to HIV, the
occurrence of drug resistant strains and the waste of
medication in health systems that are already seriously
challenged by the advent of HIV. Findings generated
from this trial may be generalized to other chronic
illnesses.
A major ethical consideration is the harm that may
arise due to accidental disclosure of status. This even-
tuality will be properly explained to the participant,
even though our message will neither disclose status nor
medication. In a study evaluating the use of mobile
phones to improve attendance to an HIV clinic in
Uganda, privacy and confidentiality were not a problem
[35]. Loss of privacy was not identified as a deterrent in
the HIVIND trial [8,36]. We are aware that most mobile
operators in Cameroon deliver mass text messages to
their clients for business, advertising, information and
sometimes health. Our intervention will be an addition
to an already existing system. Another concern is how
to manage text messaging on a larger scale, knowing
fully well that it cannot be left in the hands of mobile
operators, who will then be privy to the phone numbers
of potentially identifiable individuals. In this trial, the
operators will not be used because a framework for
cooperation that will not jeopardize confidentiality and
anonymity hasn’t been established. A single phone with
prepaid airtime will be used to deliver the text messages.
This intervention centers on the Health Belief Model
of behavior change [37]. We will collect data on modify-
ing factors (socio-demographic and disease related), per-
ceived barriers to adherence and test the efficacy of the
SMS reminder as a cue to action. Putting all these in
context will provide a better picture of who doesn’t
adheres to HAART, why they don’t adhere and if text
messages can help. Applying the SMS not only as a
reminder, but as a cue to action permits it use to resolve
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intentional and non-intentional non-adherence. In addi-
tion, we will open channels for communication between
appointments. Galovotti et al succinctly describe the key
components of an intervention aimed at bringing about
a change in behavior. The use of role models, affective
impact, and links to socio-cultural narratives, personali-
zation and knowledge of impediments and facilitators
are important features of successful behavioral interven-
tions [38].
Finally, this trial may contribute to the growing body
of evidence on the use of mobile phone technology to
improve health outcomes in low resource settings.
Abbreviations
ATC: Accredited Treatment Centre; BMI: Body Mass Index; CD: Cluster
Designation; CIHR: Canadian Institutes for Health Research; CONSORT:
Consolidated Standards for Reporting Trials; CTN: Canadian HIV Trials
Network; HAART: Highly Active Anti-Retroviral Therapy; HIV: Human Immune
Deficiency Virus; MEMS: Micro-Electronic Monitoring System; OI:
Opportunistic Infections; PRD: Pharmacy Refill Data; QOL: Quality of Life; SMS:
Short Message Service; SPSS: Statistical Package for Social Sciences; SR: Self
Report; VAS: Visual Analogue Scale; WHO: World Health Organization; YCH:
Yaoundé Central Hospital.
Acknowledgements
This study is support in part by Canadian Institutes of Health Research (CIHR)
HIV Clinical Trials Network (CTN) in the form of international postdoctoral
research fellowship award to the first author. Dr Thabane is a clinical trials
mentor for CIHR under the RCT Mentorship Programme.
Author details
1Centre for the Development of Best Practices in Health(CDBPH), Yaoundé
Central Hospital, Avenue Henri Dunant, Messa, PO Box 87, Yaoundé,
Cameroon. 2Department of Clinical Epidemiology and Biostatistics, McMaster
University, Hamilton, ON, Canada. 3Biostatistics Unit, Father Sean O’Sullivan
Research Centre, St Joseph’s Healthcare, Hamilton, ON, Canada. 4Department
of Medicine, Division of Infectious Diseases University of British Columbia,
Vancouver, BC, Canada. 5British Columbia Centre for Disease Control,
Vancouver, BC, Canada. 6Faculty of Health Sciences, University of Ottawa,
Ottawa, ON, Canada. 7Faculty of Health Sciences Stellenbosch University,
Capetown, South Africa.
Authors’ contributions
LM conceived of the study. LT, POZ, RTL, EM, JV helped to draft the
manuscript. DY, MJE, RCBM, RM, JSN, FN and HAO participated in its design
and helped draft the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 November 2010 Accepted: 7 January 2011
Published: 7 January 2011
References
1. Kaplan AW: Can the ubiquitous power of mobile phones be used to
improve health outcomes in developing countries? Global Health
2006, 2:9.
2. Lester RT, Gelmon L, Plummer FA: Cellphones: tightening the
communication gap in resource-limited antiretroviral programmes? AIDS
2006, 20:2242-2244.
3. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d’Arminio
Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD: Changing patterns
of mortality across Europe in patients infected with HIV-1. EuroSIDA Study
Group Lancet 1998, 28;352:1725-30.
4. UNAIDS: Report on global AIDS epidemic. 2009 [http://www.unaids.org/
en/media/unaids/contentassets/dataimport/pub/report/2009/
jc1700_epi_update_2009_en.pdf], (Accessed November 15, 2009).
5. Gill CJ, Davidson HH, Jonathon LS, Donald MT, Lora LS: No Complacency
about adherence to antiretroviral therapy in sub-saharan Africa. AIDS
2005, 19:1243-1249.
6. Paterson DL, Swindells S, Mohr J: Adherence to protease inhibitor therapy
and outcomes in patients with HIV infection. Ann Intern Med 2000,
133:21-30.
7. Lester R, Mills E, Kariri A, Ritvo P, Chung M, Jack W, Habyarimana J,
Karanja S, Barasa S, Nguti R, Estambale B, Ngugi E, Ball TB, Thabane L,
Kimani J, Gelmon L, Ackers M, Plummer FA: The HAART cell phone
adherence trial (WelTel Kenya1): a randomized controlled trial protocol.
Trials 2009, 10:87.
8. De Costa A, Shet A, Kumarasamy N, Ashorn P, Eriksson B, Bogg L, Diwan V,
team tHs: Design of a randomized trial to evaluate the influence of
mobile phone reminders on adherence to first line antiretroviral
treatment in South India - the HIVIND study protocol. BMC Med Res
Methodol 2010, 10:25.
9. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W,
Habyarimana J, Sadatsafavi M, Najafzadeh M, Marra CA, Estambale B,
Ngugi E, Ball TB, Thabane L, Gelmon LJ, Kimani J, Ackers M, Plummer FA:
Effects of a mobile phone short message service on antiretroviral
treatment adherence in Kenya (WelTel Kenya 1): a randomized trial.
Lancet 2010.
10. World Health Organization: UNAIDS: Resource needs for an expanded
response to AIDS in low and middle-income countries. [http://data.
unaids.org/pub/Report/2005/jc1255_resource_needs_en.pdf], (Accessed
November 20, 2010).
11. Lester R, Karanja S: Mobile phones: exceptional tools for HIV/AIDS, health,
and crisis management. Lancet Infect Dis 2008, 8:738-739.
12. Mukund Bahadur KC, Murrayb PJ: Cell Phone Short Messaging Service
(SMS) for HIV/AIDS in South Africa: A literature review. Stud Health
Technol Inform 2010, 160:530-534.
13. Liu Q, Abba K, Alejandria MM, Balanag VM, Berba RP, Lansang MAD:
Reminder systems and late patient tracers in the diagnosis and
management of tuberculosis. Cochrane Database of Systematic Reviews
2008, , 4: CD006594, Evidence Update published in June 2010.
14. Wiener L, Riekert K, Ryder C, Wood LV: Assessing medication adherence in
adolescents with HIV when electronic monitoring is not feasible. AIDS
Patient Care STDS 2004, 18:527-538.
15. Leong KC, Chen WS, Leong KW, Mastura I, Mimi O, Sheikh MA,
Zailinawati AH, Ng CJ, Phua KL, Teng CL: The use of text messaging to
improve attendance in primary care: a randomized controlled trial. Fam
Pract 2006, 23:699-705.
16. Dunbar PJ, Madigan D, Grohskopf LA, Revere D, Woodward J, Minstrell J,
Frick PA, Simoni JM, Hooton TM: A two-way messaging system to
enhance antiretroviral adherence. J Am Med Inform Assoc 2003, 10:11-15.
17. Brianna S Fjeldsoe, Alison L Marshall, Yvette D Miller: Behavior Change
Interventions Delivered by MobileTelephone Short-Message Service. Am
J Prev Med 2009, 36(2):165-173.
18. World Health Organization: Cameroon. 2010 [http://www.who.int/countries/
cmr/en/], (Accessed November 8, 2010).
19. UNICEF: Cameroon statistics. 2010 [http://www.unicef.org/infobycountry/
cameroon_statistics.html], (Accessed November 8, 2010).
20. World Health Organization: Yaoundé, Cameroon-HUG, Switzerland. 2010
[http://www.who.int/patientsafety/implementation/apps/first_wave/
cameroon_hug/en/], (Accessed November 13, 2010).
21. Simoni J, Kurth A, Pearson C, Pantalone D, Merrill J, Frick P: Self-Report
Measures of Antiretroviral Therapy Adherence: A Review with
Recommendations for HIV Research and Clinical Management. AIDS
Behav 10:227-245.
22. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian J,
Maldonado T, Duran D, Kaplan AH, Wenger NS: A Comparison Study of
Multiple Measures of Adherence to HIV Protease Inhibitors. Ann Intern
Med 2001, 134:968-977.
23. Martin S, Elliott-DeSorbo DK, Calabrese S, Wolters PL, Roby G, Brennan T,
Wood LV: A comparison of adherence assessment methods utilized in
the United States: perspectives of researchers, HIV-infected children, and
their caregivers. AIDS Patient Care STDS 2009, 23:593-601.
Mbuagbaw et al. Trials 2011, 12:5
http://www.trialsjournal.com/content/12/1/5
Page 7 of 8
24. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ,
Buono D, Eckholdt H, Howard AA, Schoenbaum EE: Antiretroviral therapy
adherence and viral suppression in HIV-infected drug users:
comparisonof self-report and electronic monitoring. Clin Infect Dis 2001,
33:1417-23.
25. SF Tools: The SF-12: An even shorter Health Survey. [http://www.sf-36.
org/tools/sf12.shtml], (Accessed November 9, 2010).
26. Abramson JH: WINPEPI (PEPI-for-Windows): computer programs for
epidemiologists. Epidemiologic Perspectives & Innovations 2004, 1:6.
27. Strandbygaard U, Thomsen SF, Backer V: A daily SMS reminder increases
adherence to asthma treatment: a three-month follow-up study. Respir
Med 2010, 104:166-171.
28. Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: Updated
guidelines for reporting parallel group randomised trials. J Clin Epidemiol
2010, 63:834-840.
29. Little RJA, Rubin DB: Statistical analysis with missing data. New York: John
Wiley & Sons; 1987.
30. Mosoko JJ, Akam W, Weidle PJ, Brooks JT, Aweh AJ, Ebad M, Kinge TN,
Vitek C, Raghunathan PL: Survival and adherence to antiretroviral therapy
in an era of decreasing drug cost in Limbe, Cameroon. Proceedings of the
14th Conference on Retroviruses and Opportunistic Infections (CROI): 25-28
February 2007; Los Angeles, California. Abstract 536 [http://www.
retroconference.org/2007/], (Accessed 28 July 2010).
31. Charles Kouanfack, Christian Laurent, Gilles Peytavin, Yvette
Mawamba Nkene, Claudine Essomba, Laura Ciaf, Maguy Ngolle,
Eric Delaporte, Alexandra Calmy, Eitel Mpoudi-Ngole’, SinataKoulla Shiro, for
the French National Agency for Research on AIDS, 1274 Study Group:
Adherence to Antiretroviral Therapy Assessed by Drug Level Monitoring
and Self-Report in Cameroon. J Acquir Immune Def Syndr 2008, 48:216-219.
32. Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantchouang R, Spire B,
Moatti JP: Financial barriers to HIV treatment in Yaoundé, Cameroon:
first results of a national cross-sectional survey. Bull World Health Organ
2009, 87:279-287.
33. World Medical Organization: Declaration of Helsinki. BMJ 1996,
313:1448-1449.
34. Reynolds NR, Testa MA, Su M, Chesney MA, Neidig JL, Frank I, Smith S,
Ickovics J, Robbins GK: Telephone support to improve antiretroviral
medication adherence: a multisite, randomized controlled trial. J Acquir
Immune Defic Syndr 2008, 47:62-68.
35. Kunutsor S, Walley J, Katabira E, Muchuro S, Balidawa H, Namagala E,
Ikoona E: Using mobile phones to improve clinic attendance amongst
antiretroviral treatment cohort in rural Uganda: A cross-sectional and
prospective study. AIDS Behav 2010.
36. Shet A, Arumugam K, Rodrigues R, Rajagopalan N, Shubha K, Raj T,
D’Souza G, De Costa A: Designing a mobile phone-based intervention to
promote adherence to antiretroviral therapy in South India. AIDS Behav
2010, 14:716-720.
37. Maimen LA, Becker MH: The health belief model: origins and correlates in
psychological theory. Health Educ Monogr 1974, 2:336-53.
38. Galavotti C, Pappas-DeLuca KA, Lansky A: Modeling and Reinforcement to
Combat HIV: The MARCH Approach to Behavior Change. Am J Public
Health 2001, 91:1602-1607.
doi:10.1186/1745-6215-12-5
Cite this article as: Mbuagbaw et al.: The cameroon mobile phone sms
(CAMPS) trial: a protocol for a randomized controlled trial of mobile
phone text messaging versus usual care for improving adherence to
highly active anti-retroviral therapy. Trials 2011 12:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mbuagbaw et al. Trials 2011, 12:5
http://www.trialsjournal.com/content/12/1/5
Page 8 of 8
